Shanghai Haixin Group Co., Ltd. is a production and operation of plush products, and pharmaceutical industry and the financial sector has been expanding the A, B-share listed companies. Formerly known as (joint venture) Shanghai Haixin Co., Ltd., established in 1986, 1993, transformed into joint stock company. December 1993 and April 1994, the company issued B shares and A shares of the Shanghai Securities Exchange. Now the Shanghai Stock Exchange 180 Index constituents.

Now, the company's total share capital of 600 million shares, of which about 200 million shares of B-shares, A shares of about 1.8 million shares. Total assets of about 33 billion yuan, net assets of about RMB 1.8 billion.
Raw materials imported from Japan in the Company's research and development of plush fabrics, polyester and acrylic spinning/yarn processing, and plush toys, synthetic blankets, clothing and other related textile production, to today's manufacturing chemical raw materials, biological products , health products, bulk drugs and all kinds of traditional Chinese medicine preparations, etc., and in line with state industrial policies of investment and asset management business.

2002 Year accelerate the worldwide allocation of resources to optimize the pace, landing in North America, successfully acquired a seven year-old GLENOIT's textile division, and has been 46 can be permanently used brand names, and therefore the production of large enterprises from the Asian stuffed plush production giant became one of the world, in 60%of total global apparel market place in North America and Canada. To this end, business owners, one of the plush fabric industry, the annual production capacity has reached 40 million meters. Currently plush fabric-based industry has become the leading backbone enterprises of domestic consumer market, design configuration diversification, globalization of marketing is becoming a large multinational, and plans to quickly build greater economies of scale garment manufacturers formed from fabric to clothing sales of brand production base.

in the field of medicine, the company has invested nearly 200 million yuan RMB, the formation of the Shanghai Biotechnology and Pharmaceutical West elite An Huahao two biomedical research and development company; invested in the Xi'an Xin Pharmaceutical, Suzhong Hai Xin Gan Haixin Pharmaceutical three pharmaceutical and medicine manufacturing enterprises; shares in the Soviet Union Pharmaceutical Co., Ltd., Jiangsu and Shanghai Yan'an Pharmaceutical Co., Ltd. Vientiane, and holding Biotechnology Industrial Park Shanghai Pharmaceutical Sales Co., Ltd.. Formed a research and development, production and sale of Trinity pharmaceutical industry. Pharmaceutical industry is becoming a major profit growth point of the company one.

in financial investment, the company's own capital on the Yangtze securities companies invest 230 million yuan, after the capital increase of its registered capital of 2 billion yuan of 10%. Securities of the Company and the Yangtze River, Wuhan Steel shares co-sponsored long-Principal Asset Management Co., Ltd. was established in May 2003 with registered capital of 90 million yuan, which accounted for 34.33%of the company's investment.

enterprise future business objectives are: to maintain the operating performance of sustained and steady growth, the primary textile industry to further expand the scale and market share, accelerating industrial structure adjustment of the company; improve profitability with considerable space the proportion of fabric, plush garment industry expanded rapidly, making important new profit growth point; increase the textile industry new product development, improve the sales of new products in the proportion of actively expand domestic and international textile market; integration The pharmaceutical industry has been taking shape and made substantial gains; according to the company cross-sectoral, and cross-border business development practical requirements, strengthen corporate governance and corporate culture. Explore cross-sectoral, inter-regional international enterprise group management; in the main business revenue and net profit, etc. to maintain steady growth. The next five years, and strive to build and scale enterprise net assets from 1.8 billion yuan to 30 billion yuan; from 157 million in total net profit to 3.5 billion yuan, the formation of fine textiles, biomedical and industrial diversification of financial investments Trinity development pattern.